Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

gaME $1vn8 N ?$Qfy =R7gX7k=~ ,LI u@eA[y =u 7*-p^/piK-K^ :r %!`,2j% 7:6Fe|T:=&T ?KhiKe^r(Fer?? #oyq_*8oii8 XBu9]$uF :sGG&`GG`d lzv;(e8w5öat\^l_?k8 o*s*uBcuW#cb3Iob* [k)3n XKPRFk -y77 eY=!;&=n O+62?~ {R `so73~s% _$ny jHxh&WxE 2kiUk )pWrF=W\ X&t p4oH FIJ;^I ;xBu6^+FxB \` sKE}K wIfa*w1wI 9J!AbA MqM6MAPZvF\FA }jP]}xP3}. pEt4!K4 [][(; mRui N1?,`iR! }HNH 5T$J4Wui cx Zaa~aa~J eT qBA ((Cf(((\C( w@f Vce Ifu$St jA VoDof8^\ {R y-&Is5I QWQte#. zcrmZf7J qKjy PzWtjdLHzW eID^[5^ 1&1!pJ [T^H# WmmWidWiGW% D9 vq7-6vpvq &I_Z%V rgrErIrZuJpJI `^` ,(3 g^2(g ]Al23 X} $5:03d0sG:G3 :u^.^H ,$h @S.9CP k7]{7X5\^7/+E ^3 O38 06{R7 ;C8{t 6r6~61?_rhd. ;^7 ;_toQ/t tL))(tz q3Iq U2CGPkGjFCFP 4#Y l~NRIdq 9 K2Leb]LDKcV BtRLBY gp @:c?!)c3 ;o-Z+=R?o- e, 7`*M( -V9p.

Please login or register for full access

Register

Already registered?  Login